AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05207241 — intervention group
Intervention type: OTHER
Intervention: provides guidance on gravitationally assisted breastfeeding
Description: Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
Study NCT05880407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SERI osteotomy
Description: Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
Study NCT06151626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing and muscle relaxation exercises
Description: 5 minutes of breathing and muscle relaxation exercises
Study NCT06005987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal application
Description: Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
Study NCT05880407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous osteotomy according to Chevron
Description: Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
Study NCT05556889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a modified auriculotemporal nerve blockade
Description: Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
Study NCT03760614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
Study NCT03760614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
Study NCT05255926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-pentixafor
Description: All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
Study NCT05556889 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional auriculotemporal nerve blockade
Description: Traditional auriculotemporal nerve blockade
Study NCT05255926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
Study NCT04940949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF90103
Description: Lu AF90103 - powder for solution for infusion
Study NCT05197140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food: cooked 85% lean ground beef
Description: see arm description
Study NCT05197140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food: Impossible Burger (R)
Description: see arm description
Study NCT06100484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
Study NCT05871229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Photodynamic antibacterial dual-light device with a marker substance
Study NCT05871229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment for peri-implantitis
Description: Standard treatment for peri-implantitis as per international, national and clinic guidelines
Study NCT05871229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment for peri-implantitis
Description: Standard treatment for peri-implantitis as per international, national and clinic guidelines
Study NCT06113757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signal Therapy provided by Dr.Biolyse device
Description: Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
Study NCT06113757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Support Treatment
Description: The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
Study NCT06348953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selective caries removal and conventional non-bioactive restorative system
Description: conventional dental restorative adhesive and resin based composite
Study NCT06348953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selective caries removal and bioactive restorative system
Description: bioactive dental restorative resin based system
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200mg IV D1~1 cycle every 21 days
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days
Study NCT04940949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - powder for solution for infusion
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days
Study NCT06051851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days
Study NCT05871593 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Molecular genetic diagnostic
Description: With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
Study NCT05331157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
Study NCT05690503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: Medication infusion intravenously over 90 minutes.
Study NCT05690503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581b
Description: Medication infusion intravenously over 90 minutes.
Study NCT05136118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
Study NCT06307782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein intake before surgery
Description: Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
Study NCT06307782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water before surgery
Description: Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
Study NCT05134896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatial light modulator
Description: This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
Study NCT04662411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: acute intake of 0 mg butyrate and hexanoate
Study NCT04662411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 1
Description: acute intake of 650 mg butyrate and hexanoate
Study NCT04662411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 2
Description: acute intake of 1325 mg butyrate and hexanoate
Study NCT04662411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 3
Description: acute intake of 2000 mg butyrate and hexanoate
Study NCT04992039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO HEARTS technical package
Description: Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling.
Study NCT04735965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
Study NCT04735965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
Study NCT04735965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placeb
Description: Equal volume of normal saline to dexmedetomidine and meperidine group.
Study NCT05491655 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Intensity His Bundle pacing
Description: All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
Study NCT05491655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity His Bundle pacing
Description: All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
Study NCT06190535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etamsylate
Description: Enteral administration of Etamsylate as solution galenic form
Study NCT04666714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praga formulation
Description: Praga formulation tablet
Study NCT04666714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo pregabalin 75mg
Description: Placebo pregabalin 75mg tablet
Study NCT04666714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Pregabalin 150mg
Description: Placebo Pregabalin 150mg tablet
Study NCT04666714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Pregabalin 75mg tablet
Study NCT06163560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app Happy Baby HK
Description: Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers.
Study NCT06163560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Family Health Service parenting booklet
Description: The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
Study NCT05508243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic Nasal Spray
Description: Health care product - nasal application
Study NCT05998252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alveo HP Balloon Dilatation Catheter
Description: Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
Study NCT05843708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 40 mg Oral Tablet
Description: Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)
Study NCT05843708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg Oral Tablet
Description: Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
Study NCT05843708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 10 mg Oral Tablet
Description: Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
Study NCT05074069 — intervention group
Intervention type: PROCEDURE
Intervention: Gynaecological reconstruction
Description: Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
Study NCT04701866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
Study NCT06514027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsules
Description: BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
Study NCT06514027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium for Injection
Description: Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
Study NCT06514027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Study NCT04666714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg tablet
Study NCT04666714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Praga formulation
Description: Placebo Praga formulation tablet
Study NCT05467046 — intervention group
Intervention type: DEVICE
Intervention: Smartwatch system
Description: The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
Study NCT04831372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off Table Group
Description: Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
Study NCT04831372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On Table Group
Description: Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
Study NCT06514027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Study NCT06514482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Diagnosis
Study NCT05654766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
Study NCT05654766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation and plasma coagulation
Description: Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
Study NCT05329779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexanolone
Description: Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
Study NCT05329779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo is a 0.45% sodium chloride infusion.
Study NCT05123742 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Testing
Description: Testing for the SARS-CoV-2 virus
Study NCT05833685 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06089161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants in this group will receive standard of care treatment for sleep apnea.
Study NCT06089161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants in this group will receive standard of care treatment for sleep apnea.
Study NCT06089161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized OSA Treatment
Description: Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
Study NCT04859842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Electromagnetic Field
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
Study NCT04859842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
Study NCT04859842 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
Study NCT05748730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCHART
Description: The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider.